Kidney transplantation is the best therapy method for patients with uremia. The main factors affecting the long-term survival of the graft were chronic antibody-mediated rejection and the death of the patients. Newborn donor special antibody (DSA) is a major risk factor for chronic antibody-mediated rejection (AMR) and poor transplantation outcomes. Detection of mycophenolate mofetil (MMF) trough concentration can help estimate its exposure. Deficient exposure of MMF can lead to AMR after transplantation surgery. The aim of this study is to estimate the risk factors of one-year DSA after transplantation.
Study Type
OBSERVATIONAL
Enrollment
300
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
DSA 12 month
newborn DSA in recipient serum in the first 12 month after transplantation
Time frame: 2021.5-2023.5
DSA 6 month
newborn DSA in recipient serum in the first 6 month after transplantation
Time frame: 2020.12-2022.12
DSA risk factors
risk factors of newborn DSA
Time frame: 2020.5-2023.5
MPA-AUC
trough concentration of MMF in recipients' serum
Time frame: 2020.5-2023.5
AR
AMR after transplantation
Time frame: 2020.5-2023.5
allograft function
serum creatinine and creatinine clearance in 1 year after transplantation
Time frame: 2021.5-2023.5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.